CHA AI Healthkare
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CHA AI Healthkare develops and makes skincare, makeup, and personal-care products for everyday consumers.
It is listed on KOSPI, South Korea's main stock exchange, and pursues international distribution through digital channels. The company's product development is grounded in dermatological science and high-performance ingredients, with an active focus on expanding lines for sensitive skin and incorporating customisable formulation technology.
Summary is AI-generated and may contain errors · figures from DART filings
CHA AI Healthkare in five facts
What does CHA AI Healthkare do?
CHA AI Healthkare develops and makes skincare, makeup, and personal-care products for everyday consumers.
Where is CHA AI Healthkare listed and in which sector?
CHA AI Healthkare (Korean name: 차AI헬스케어) trades under KRX code 025620 on KOSPI, the main board of the Korea Exchange. It is classified in the Materials sector, Chemicals.
How large is CHA AI Healthkare?
Its market capitalisation was US$74.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CHA AI Healthkare's latest annual revenue and operating profit?
For fiscal year 2025, CHA AI Healthkare reported revenue of US$5.5M, an operating loss of US$5.6M and net income of US$1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 53.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signedSupply contract · Jun 22
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jun 19
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jun 19
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jun 19
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jun 19
- Decision to acquire shares/equity in another company
CHA AI Healthkare disclosed an acquisition, worth US$13.1M.
M&A · Jun 18 - Material event report (equity acquisition)M&A · Jun 18
- [Amended] Material event report (convertible bonds)
CHA AI Healthkare updated the terms of convertible bonds to raise US$1.63M, about 2.5% of its market value.
Capital raise · Jun 18 - [Amended] Material event report (convertible bonds)
CHA AI Healthkare updated the terms of convertible bonds to raise US$1.63M, about 2.5% of its market value.
Capital raise · Jun 18 - [Amended] Material event report (convertible bonds)
CHA AI Healthkare updated the terms of convertible bonds to raise US$3.25M, about 5.1% of its market value.
Capital raise · Jun 18 - [Amended] Material event report (convertible bonds)
CHA AI Healthkare updated the terms of convertible bonds to raise US$3.25M, about 5.1% of its market value.
Capital raise · Jun 18 - [Amended] Supply contract signed
CHA AI Healthkare updated a previously disclosed supply contract with IWORLD, now worth US$839K, about 7.99% of its recent annual revenue, running through Jun 2026.
Supply contract · May 15 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
CHA AI Healthkare reported consolidated results for FY2025: revenue of US$4.97M (−53.4% year on year), an operating loss of US$5.23M and net income of US$179K (from a loss a year earlier).
Earnings · Feb 6